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Prospective randomized study on bilateral above-
knee femoropopliteal revascularization:
Polytetrafluoroethylene graft versus reversed
saphenous vein
Enzo Ballotta, MD, Laura Renon, MD, Michele Toffano, MD, and Giuseppe Da Giau, MD, Padua, Italy
Objective: Some controversy exists as to whether polytetrafluoroethylene (PTFE) is equivalent to reversed saphenous vein
(SV) as bypass graft material for above-knee femoropopliteal revascularization. We compared the 5-year patency rate with
reversed SV and PTFE grafts in patients with claudication who underwent bilateral above-knee femoropopliteal
revascularization.
Methods: Between January 1994 and December 1997, 51 patients (102 limbs) with bilateral disabling claudication due to
superficial femoral artery occlusion underwent above-knee femoropopliteal bypass grafting, with SV in one limb and
PTFE graft in the other limb. Patients were randomly selected for sequential surgical treatment with either SV-PTFE or
PTFE-SV. Kaplan-Meier analysis was used to estimate patency rate, and various factors were analyzed to ascertain any
association with revascularization failure.
Results: There was no perioperative (30 day) limb loss or death, but five late deaths (late survival rate, 90%). Mean
follow-up was 59 months. In the SV group, three bypass grafts failed, requiring repeat operation in only one patient. In
the PTFE group, eight bypass grafts failed, leading to five repeat operations. There was no statistically significant
difference in primary “assisted” patency rate for the two grafts: 100%, 98%, and 94% for SV grafts, and 96%, 84%, and 84%
for PTFE grafts (P  .09), after 1, 3, and 5 years, respectively.
Conclusions: The overall results of this randomized study show that SV and PTFE grafts have a statistically comparable
patency rate when used above the knee in patients with claudication. Use of SV, however, leads to fewer occlusions and
repeat operations. (J Vasc Surg 2003;38:1051-5.)
Autogenous saphenous vein (SV) is the most effective
and durable conduit for infrainguinal vascular reconstruc-
tion in patients with claudication or critical ischemia (rest
pain, gangrene). While SV is the undisputed graft of choice
when the distal anastomosis must be made to the below-
knee popliteal or the more distal tibioperoneal arteries,1-3
some controversy exists as to whether polytetrafluoroeth-
ylene (PTFE) is equivalent to SV when the distal anasto-
mosis is above the knee, particularly in patients with clau-
dication, given the satisfactory early results achieved in
nonrandomized studies.4-7 Supporters of the preferential
use of PTFE for above-knee femoropopliteal revasculariza-
tion claim shorter operative time, lower morbidity from the
more limited dissection, and, especially, preservation of the
SV for future use, such as coronary artery bypass revascu-
larization or for ipsilateral below-knee bypass grafting when
previous prosthetic grafting has failed.
Before we began this study in 1994, there was only one
randomized study with long-term follow-up comparing SV
and PTFE for above-knee femoropopliteal bypass grafting.
In that study, no significant difference emerged in patency
rate between SV and PTFE after 4 years.8 Since then, three
further randomized trials comparing SV with PTFE in
above-knee femoropopliteal revascularizations have been
published, with divergent long-term results.9-11 Two stud-
ies reported significantly better primary patency and limb
salvage rates with SV than with PTFE after 5 years,10,11
whereas the third study (the only study other than ours to
compare SV and PTFE in above-knee bypass grafting in
patients with claudication needing bilateral arterial recon-
struction) found that SV and PTFE had comparable pa-
tency rate after 5 years.9
The purpose of our prospective randomized study was
to compare 5-year patency rate of SV versus PTFE in
patients with claudication after bilateral above-knee femo-
ropopliteal revascularization with SV in one limb and PTFE
in the contralateral limb.
PATIENTS AND METHODS
The study included 51 patients (102 limbs) who un-
derwent bilateral above-knee femoropopliteal revascular-
ization to treat disabling claudication after failure of a
nonsurgical protocol (ie, earlier risk modification and grad-
ual exercise with or without pharmacologic therapy) be-
tween January 1994 and December 1997 at our institution.
All patients had angiographic evidence of a long superficial
femoral artery occlusion and above-knee rehabitation of the
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popliteal artery with one to three runoff vessels. Good
runoff was defined as the popliteal artery and two or three
vessels patent to the foot. Poor runoff was defined as either
one tibial vessel patent to the foot or the popliteal artery
ending blindly below the knee. Treatment consisted of
reversed SV graft in one limb and PTFE graft in the
contralateral limb. All eligible patients who agreed to take
part in the study were randomized by means of sealed
envelopes that had been independently prepared with a
computer-generated randomization schedule. They were
randomized for sequential surgical treatment involving ei-
ther SV-PTFE or PTFE-SV. All bilateral procedures were
generally performed 6 to 8 weeks apart. Informed consent
was obtained from all patients, and the study was approved
by the Ethical Committee of our institution. All PTFE
grafts were 8 mm in diameter (thin-walled expanded PTFE
graft [Gore-Tex]; W. L. Gore & Associates, Flagstaff, Ariz).
All surgical procedures were performed by the same sur-
geon, with the patient under regional (epidural or spinal)
anesthesia. Preoperative risk factors, including coronary
artery disease, hypertension, hyperlipidemia, diabetes mel-
litus, prior inflow reconstruction, and history of smoking
and stroke, were determined for each patient. Physical
findings recorded included peripheral pulses and Doppler
pressure measurements at high thigh, low thigh, calf, and
ankle levels. Ankle pressure was compared with higher
brachial pressure to obtain the ankle-brachial index (ABI)
at these levels. Patients with uncompressible vessels, ABI
greater than 0.9, SV already removed, or previously placed
ipsilateral prosthetic or SV femoropopliteal above-knee or
below-knee bypass graft were excluded. Other exclusion
criteria were short life expectancy (1 year), popliteal
aneurysm disease, serum creatinine concentration greater
than 2.0 mg/dL, polycythemia (red blood cell count7.5
 106/mm3), or platelet count greater than 106/mm2. All
patients were required to have adequate segments of SV
available for revascularization on the basis of duplex scan
venous mapping (adequacy defined as compliant vein with
a diameter of at least 4 mm proximally and 3 mm distally).
Composite or sequential bypass grafts were excluded.
Completion angiography was not part of the operative
protocol. All anastomoses were made end-to-side with
continuous 5/0 polypropylene suture (Prolene; Ethicon,
Somerville, NJ), proximal to the ipsilateral common femo-
ral artery and distal to the above-knee popliteal artery. In all
procedures, intravenous heparin (5000 IU) was adminis-
tered before clamping; blood pressure was maintained at
average preoperative level or slightly higher. Hepariniza-
tion was not reversed with protamine. Thrombin-soaked
oxidized cellulose and digital pressure were applied to stop
any bleeding before closure.
Oral warfarin therapy (Coumadin; DuPont, Wilming-
ton, Del) was started the day before the operation and was
continued for 6 months, aiming for a normalized ratio
between 2 and 4. After 6 months, 325 mg of aspirin was
taken daily.
Graft surveillance. Postoperative evaluation included
history, physical examination, and hemodynamic profile in
all patients at discharge, at 4 weeks and 3, 6, and 12
months, and every 6 months thereafter. The graft surveil-
lance protocol also included duplex ultrasound (US) scan-
ning, with ABI. Color duplex US scans were defined as
abnormal if peak systolic flow velocity was more than twice
the velocity in the adjacent graft or if peak systolic velocity
throughout the graft was uniformly less than 45 cm/s. The
absence of color flow in these grafts was indicative of graft
occlusion warranting further evaluation with conventional
arteriography. All criteria used for this trial conformed with
standards suggested by the Ad Hoc Committee of the Joint
Council of the Vascular Societies for Reports Dealing with
Lower Extremity Ischemia.12,13
Patency rates reported in this analysis are cumulative
primary “assisted” patency rates,12,13 because remedial sur-
gery for late bypass stenosis was not considered a patency
failure. Secondary patency rates, that is, patency of the
original graft that thrombosed but was maintained patent
with thrombectomy, thrombolytic therapy, percutaneous
angioplasty, or patch graft angioplasty, were not considered
in this study.
Statistical analysis. Continuous data were compared
with the Student t test. Proportion and categorical data
were compared with 2 analysis or the Fisher exact test, as
appropriate. All tests were two-tailed. Statistical signifi-
cance was inferred at P .05. Life table analysis was used to
calculate cumulative patency rates, and group data were
compared with the log-rank test.
RESULTS
Baseline data for the 51 study patients are given in
Table I. Mean preoperative ABI were comparable for the
SV (0.53  0.07) and PTFE (0.54  0.07) groups. Out-
flow arteries were fairly evenly distributed between the two
groups: one vessel in 8 patients in the SV group and 5
patients in the PTFE group, two vessels in 18 patients in the
SV group and 20 patients in the PTFE group, and three
vessels in 25 patients in the SV group and 26 patients in the
Table I. Patient demographic data
n %
Patients 51
Procedures 102
Age (y)
Mean 62
Range 47-82
Male gender 33 65
Hypertension* 31 61
Coronary artery disease 13 25
Smoking† 44 86
Diabetes mellitus 27 53
Hyperlipidemia‡ 22 43
History of stroke 12 23.5
Previous ipsilateral inflow procedure 8 16
*Defined as elevated blood pressure treated with medication.
†Defined by patient history.
‡Defined as elevated cholesterol or triglyceride concentrations treated with
medication.
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PTFE group. A patent but calcified popliteal artery neces-
sitated local endarterectomy at the distal arteriotomy level
before performing the anastomosis in 18 patients (18%), 10
in the SV group and 8 in the PTFE group. Three coronary
bypass reconstruction procedures (6%) were performed,
but none used SV.
Morbidity and mortality. Perioperative complica-
tion rates were 14% for the SV group and 12% for the PTFE
group. One patient in the PTFE group had perioperative
pneumonia; 5 patients—3 in the SV group and 2 in the
PTFE group—had deep vein thrombosis; 2 patients in each
group had significant bleeding that required surgical explo-
ration; and 3 patients—2 in the SV group—had noninfec-
tious wound complications (ie, lymphocele and seroma).
There was no perioperative (30 day) limb loss or death in
this series, but there were five late deaths, three due to
myocardial infarction and two due to cancer (late survival
rate, 90%). At last follow-up, both bypass grafts were patent
in all 5 patients. Median observation time before death was
637 days.
Long-term patency. Patient follow-up was approxi-
mately 5 years (mean, 59 months; range, 1-108 months).
Only 1 patient, in the PTFE group, required postoperative
revision of a patent prosthetic revascularization; no SV
bypass procedures required revision. Given this extremely
low incidence of revision during follow-up, we identified
primary and primary “assisted” patency rates, and the re-
sults are reported as primary assisted patency rate. There
was no statistically significant difference in primary assisted
patency rate between the two groups: patency after 1, 3,
and 5 years was 100%, 98%, and 94% for SV bypass grafts,
and 96%, 84%, and 84% for PTFE grafts (P .09; Fig). No
revascularization failure was related to inflow disease.
Three bypass grafts failed in the SV group, one within
the first 24 months and two others 42 and 52 months,
respectively, after surgery. Popliteal artery lesions, repre-
senting either neointimal hyperplasia or progression of
occlusive disease, were thought to be responsible. No re-
peat operation was performed in two patients, because they
had only mild claudication. In the third patient, with poor
runoff, onset of rest pain prompted creation of a new bypass
graft extending below the knee, using the contralateral SV.
This new revascularization is patent to date.
Eight bypass grafts failed in the PTFE group; most (5 of
8) unsuccessful revascularizations failed within the first 24
months, and all failed within 3 years. Distal anastomoses
necessitated previous endarterectomy in two patients. No
repeat operation was scheduled in three patients, because
they had only mild claudication and chose to live with the
problem, deferring further surgery until the symptoms
worsened. New bypass grafts were subsequently needed in
five patients with disabling claudication (n 1) or rest pain
(n 4). In one patient a new above-knee bypass procedure
was performed, with the ipsilateral SV; in the other four
patients the reconstruction was extended below the knee,
with the ipsilateral SV. When primary assisted patency rates
were correlated with outflow, the number of patent tibial
arteries did not affect 5-year patency rate in either the SV or
PTFE groups. In addition, analysis of demographic data
and preoperative risk factors showed no significant predic-
tive value for age, sex, diabetes mellitus, coronary artery
disease, hypertension, or cigarette smoking, with regard to
failure of either the SV or PTFE bypass revascularizations.
No major amputation was necessary during follow-up
in the two groups.
DISCUSSION
The hypothesis of this randomized study was that it
would be useful to compare SV and PTFE grafts in above-
knee femoropopliteal bypass procedures in patients with
claudication undergoing bilateral arterial revascularization,
with SV in one limb and a PTFE graft in the other limb.
Each patient would serve as his or her own control, inas-
much as both procedures would be affected by the same
systemic risk factors and demographic data. Any bypass
graft failure occurring in one limb would consequently be
related to local factors and, essentially, to the type of
conduit involved.
Above-knee femoropopliteal bypass grafting per-
formed with randomized SV and PTFE grafts demon-
strated similar 5-year primary assisted patency rates, al-
though there was a slight trend toward a superior patency
rate with SV graft (94% vs 84%; P  .09). In Table II the
long-term outcome for the present series is compared with
findings of four previously published randomized trials8-11;
two studies found no statistically significant difference be-
tween the grafts,8,9 and the other two reported significant
superiority of SV graft.10,11 In 1986 Veith et al8 reported
the largest published prospective study comparing SV and
PTFE for infrainguinal bypass grafting, which included 845
infrainguinal bypass grafts, 176 of which were to the above-
knee popliteal artery. The indication for surgery was critical
ischemia in 87% of patients, and 15% had undergone pre-
vious bypass grafting. Four-year primary patency rate was
61% for SV and 38% for PTFE (P .25), but only 14 of the
original 176 patients were available for follow-up at 4 years.
More recently, AbuRahma et al9 compared 5-year primary
Primary “assisted” patency rate over time for saphenous vein grafts
(diamonds) versus polytetrafluoroethylene grafts (squares). Stan-
dard error is less than 5% for all time points (Kaplan-Meier
method).
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patency rate of SV and PTFE grafts in 43 patients (86
limbs) with bilateral disabling claudication treated with SV
in one limb and with PTFE in the other limb. Although the
primary patency rate was better for SV (76% vs 68%), the
difference was not statistically significant. Here again, how-
ever, the number of patients available for long-term fol-
low-up (n 13) was too small for a meaningful estimate of
graft patency. In the prospective cooperative study of the
Department of Veterans Affairs,10 752 patients were ran-
domized to receive either PTFE grafts (n 265), SV grafts
(n  226), or human umbilical vein grafts (n  261) for
above-knee femoropopliteal bypass, mainly to treat critical
ischemia (67%). After 5 years, SV grafts had a significantly
better patency rate compared with PTFE grafts (73% vs
39%; P .01). Similar outcome was reported by Klinkert et
al11 in a series of 151 above-knee femoropopliteal revascu-
larization procedures (75 SV grafts vs 76 PTFE grafts)
performed, especially in patients with claudication (79%).
These authors found a significantly better 5-year patency
rate for SV than for PTFE grafts (76% vs 58%; P  .03),
although the same investigators reported in an earlier arti-
cle on the same patients that there was no statistically
significant difference between SV and PTFE grafts after 2
years of follow-up (83% vs 67%, respectively; P  .06).14
Moreover, if we compare patency rates for SV and PTFE
grafts in all five randomized trials, primary patency is better
for SV grafts at all intervals, and overall the long-term
patency rate was more favorable for both grafts in the series
that included only patients with claudication, although the
difference was not statistically significant.
While some might interpret our excellent 5-year pa-
tency rate with both grafts as meaning there is no clinically
significant difference between the two prosthetic materials,
it is more likely that this is a type II statistical error due to
inadequate sample size. Moreover, although the data
emerging from the present series do not enable any conclu-
sions to be drawn, they nonetheless prompt several consid-
erations.
Unlike the finding reported by Veith et al8 that SV and
PTFE grafts to the popliteal artery failed with nearly equal
frequency up to 18 months and that thereafter PTFE grafts
failed more frequently, most (5 of 8) of the unsuccessful
PTFE revascularizations in our series failed within the first
24 months, and all within 3 years, whereas only one SV
revascularization failed within the first 24 months, and two
others failed 42 and 52 months after surgery. In addition to
the nearly threefold occlusion rate (8 vs 3), five patients in
the PTFE group required repeat operation, as opposed to
only one patient in the SV group, a fivefold difference. Thus
approximately 10% of patients originally operated on to
treat claudication had limb-threatening ischemia after fail-
ure of the initial PTFE graft reconstruction; the SV was
used in all repeat operations. This confirms that when
PTFE is used first, there is a higher likelihood that repeat
operation will be necessary if the reconstruction fails, be-
cause the original symptoms more often tend to become
more severe.5,8,15,16 It is hard to account for this higher
incidence of limb-threatening ischemia after PTFE graft
occlusion than after SV graft occlusion; inasmuch as no
revascularization failure was due to progression of inflow
disease, and because indication for surgery and level of
anastomosis were the same in the two groups, distal runoff
impairment might explain this issue. Inasmuch as the de-
gree of preoperative runoff was comparable in our two
groups, whereas worsening tibial runoff might be partially
due to progressive atherosclerotic disease, we cannot rule
out the possibility that PTFE grafts tend to cause tibial
thromboembolism, given the greater inherent thrombo-
genic potential of prosthetic versus venous material.15 The
data drawn from a comparison of preoperative and postop-
erative conventional angiograms were not sufficient to sup-
port any conclusions, however. On the other hand, Burger
et al14 found a high occlusion rate in a group of PTFE
bypass grafts with excellent three-vessel runoff; no explana-
tion was provided for this finding.
None of our patients needed the SV for coronary
bypass graft procedures, although three coronary bypass
reconstructions were performed during follow-up. The in-
creasing use of mammary arteries and percutaneous tech-
niques has much reduced the need for coronary vein bypass
graft procedures, so the recommendation to preferentially
use synthetic grafts for above-knee femoropopliteal revas-
cularization so as to save the SV for future coronary bypass
grafting appears questionable. Many other experiences also
fail to support the need to save autologous material for later
use.4,9,11,17,18
The overall low rate of adverse events (11 graft occlu-
sions) could explain why none of the risk factors described
in other studies (smoking habit, diabetes mellitus, poor
runoff, age, sex) influenced the patency rate of our bypass
Table II. Comparisons of primary patency rates of SV and PTFE bypass grafts from randomized controlled trials
Year
Veith et al 8 Johnson and Lee10 Klinkert et al11 AbuRahma et al9 Present study
SV PTFE SV PTFE SV PTFE SV PTFE SV PTFE
1 82 82 84 77 81 80 88 81 100 96
2 79 69 81 69 77 69 78 68 98 90
3 70 56 77 58 76 61 76 68 98 84
4 61 38 75 50 76 58 76 68 94 84
5 74 39 76 52 76 68 94 84
All values represent percent.
SV, Saphenous vein; PTFE, polytetrafluoroethylene.
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grafts. Only Prendiville et al,5 in a retrospective study of
114 above-knee femoropopliteal PTFE reconstructions,
found that cigarette smoking, diabetes mellitus, and num-
ber of patent tibial arteries affected patency of PTFE revas-
cularizations.
In conclusion, in this randomized study SV and PTFE
grafts for above-knee bypass procedures demonstrated
comparable 5-year patency rates in patients with claudica-
tion undergoing bilateral femoropopliteal revasculariza-
tion. Use of SV nonetheless results in fewer occlusions and
fewer repeat operations.
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